Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alimera Sciences Inc (ALIM)

Alimera Sciences Inc (ALIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,634
  • Shares Outstanding, K 71,009
  • Annual Sales, $ 46,970 K
  • Annual Income, $ -16,380 K
  • 60-Month Beta 1.99
  • Price/Sales 0.51
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.16
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 10/29/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.33 +8.76%
on 10/18/19
0.69 -47.83%
on 09/24/19
-0.14 (-28.00%)
since 09/20/19
3-Month
0.32 +12.15%
on 09/09/19
0.95 -62.08%
on 07/29/19
-0.51 (-58.50%)
since 07/22/19
52-Week
0.32 +12.15%
on 09/09/19
1.21 -70.25%
on 03/06/19
-0.60 (-62.50%)
since 10/22/18

Most Recent Stories

More News
Alimera Sciences to Report Third Quarter 2019 Financial Results on Tuesday, October 29, 2019 and Provide Corporate Update

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will...

ALIM : 0.36 (unch)
Alimera Obtains Marketing Authorization for ILUVIEN(R) in Portugal for the Treatment of Non-Infectious Posterior Uveitis

Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that INFARMED,...

ALIM : 0.36 (unch)
Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces top-line...

ALIM : 0.36 (unch)
Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN(R) to be Presented at the American Academy of Ophthalmology Annual Meeting

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical...

ALIM : 0.36 (unch)
Ocular Inflammation Treatment Market Latest In-Depth Report Segment by Manufacturers, Type, Applications and Dynamics

A recent report provides crucial insights along with application based and forecast information in the Global Ocular Inflammation Treatment Market. The report provides a comprehensive analysis of key factors...

AKRX : 4.77 (+1.27%)
ALIM : 0.36 (unch)
AGN : 174.92 (+0.13%)
NVS : 86.67 (-0.34%)
PFE : 36.43 (-0.08%)
VRX.TO : 30.80 (-3.33%)
Global Ocular Drug Delivery Technology Market Growth, Indepth Insight And Research Finding To 2019-2028

Ocular Drug Delivery Technology Market report 2019 is dispensed after a thorough study of various key market segments like Market Size, Latest Trends, Market Threats & . Ocular Drug Delivery Technology...

ALIM : 0.36 (unch)
AGN : 174.92 (+0.13%)
NVS : 86.67 (-0.34%)
OCUL : 3.62 (+6.47%)
PFE : 36.43 (-0.08%)
VRX.TO : 30.80 (-3.33%)
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN(R) in Benelux Countries

Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has...

ALIM : 0.36 (unch)
Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management

Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that...

ALIM : 0.36 (unch)
Ocular Inflammation Treatment Market Is Growing At an Exponential Rate in 2019 and Coming Years

The global Ocular Inflammation Treatment market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2019 to 2026.

AKRX : 4.77 (+1.27%)
ALIM : 0.36 (unch)
AGN : 174.92 (+0.13%)
NVS : 86.67 (-0.34%)
PFE : 36.43 (-0.08%)
VRX.TO : 30.80 (-3.33%)
Alimera Sciences Launches ILUVIEN(R) in Germany For Non-Infectious Uveitis Indication

Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will...

ALIM : 0.36 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ALIM with:

Business Summary

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes...

See More

Key Turning Points

2nd Resistance Point 0.39
1st Resistance Point 0.37
Last Price 0.36
1st Support Level 0.35
2nd Support Level 0.34

See More

52-Week High 1.21
Fibonacci 61.8% 0.87
Fibonacci 50% 0.77
Fibonacci 38.2% 0.66
Last Price 0.36
52-Week Low 0.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar